Shangke Huang

Shangke Huang

Auto-generated profile, based on publicly available information

Shangke Huang

Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
YZYujiao Zhang
Yujiao Zhang
YFYizeng Fan
Yizeng Fan
SHShangke Huang
Shangke Huang
GWGuanying Wang
Guanying Wang
RHRui Han
Rui Han
XZXinhan Zhao
Xinhan Zhao
Thymoquinone (TQ, 2‐methyl‐5‐isopropyl‐1,4‐benzoquinone), a bioactive constituent extracted from the seeds of Nigella sativa, has been proved to exert anti‐tumor efficiency in various cancers. Autophagy is a self‐digestion phenomenon, and its role in tumor formation and progression remains controversial. In the present study, we investigated the effects of TQ on renal cell cancer (RCC) cell lines (786‐O and ACHN) using wound healing assay, transwell assay and western blot analysis. We found that TQ effectively inhibited the metastatic capacity of RCC cells in vitro, which was also verified in a xenograft model. Meanwhile, we observed LC3 puncta and detected the expression of LC3 in TQ‐treated RCC cells, and then found that autophagy was induced by TQ in 786‐O and ACHN cell lines. In addition, TQ inhibited the migration and invasion as well as the EMT in RCC cells in an autophagy‐dependent manner. To further explore the underlying mechanism, we detected the AMPK/mTOR signaling pathway. The results indicated that TQ inhibited the metastasis of RCC cells by inducing autophagy via AMPK/mTOR signaling pathway. In conclusion, our findings provide a novel therapeutic strategy that aims at TQ‐induced autophagy in RCC treatment.

25 March 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
SHShangke Huang
Shangke Huang
LFLu Feng
Lu Feng
GAGaili An
Gaili An
XZXiaojin Zhang
Xiaojin Zhang
ZZZixuan Zhao
Zixuan Zhao
LZLingxiao Zhang
Lingxiao Zhang
Distinguishing the surface markers of cancer stem cells (CSCs) is a useful method for early diagnosis and treatment of tumors, as CSCs may participate in tumorigenesis and metastasis by migrating into the circulatory system. However, the potential targets of CSCs are expressed at low levels in the natural state and are always changing. Thus, dynamic screening has been reported to be an effective measure for exploring CSC markers. In recent years, diverse single‐chain variable fragments (scFvs) have been widely used in immunotherapy. In this study, we determined that the scFvs, screened using RD, had a high affinity to microspheres and could inhibit their progression. We also observed that the selected scFvs underwent evolution in vitro, and antitumor‐associated proteins were successfully expressed. Combined with chemotherapy, the scFvs had a synergistic effect on the inhibition of the microspheres’ progression in vitro and in vivo, which could be ascribed to their high affinity for stem‐like cells and the inhibition of the microspheres’ collective behaviors. In addition, proteins inhibiting CD44+/CD24+ and MAPK were involved. Our data indicated that dynamic screening of the scFvs in a natural state was of great significance in the inhibition of the microspheres in vitro and in vivo.

21 March 2014 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
XZXiaoxiao Zuo
Xiaoxiao Zuo
YQYan Qin
Yan Qin
XZXiaojin Zhang
Xiaojin Zhang
QNQian Ning
Qian Ning
SSShan Shao
Shan Shao
XZXinhan Zhao
Xinhan Zhao
ARHI is a maternally imprinted tumor suppressor gene that is expressed in normal breast epithelial cells but not in most breast cancer cells. Aberrant methylation and hypernomic histone deacetylation have been implicated in the silencing of ARHI. To investigate the mechanism of ARHI induction, MDA-MB-231 breast cancer cells were either transfected with the eukaryotic expression vector, pcDNA3.1(+)-ARHI, or were simultaneously treated with a histone deacetylase inhibitor, [trichostatin A, (TSA)] and the methyltransferase inhibitor, 5-aza-2'-deoxycytidine (DAC). The latter treatment group also included the targeting of ARHI by small interfering RNA (siRNA) to further examine interactions between ARHI and the drugs applied. Levels of ARHI were detected by western blotting, MTT assays were used to evaluate cell proliferation, and both cell cycle progression and apoptosis were detected using flow cytometry. Both the transfection of pcDNA3.1(+)‑ARHI and the application of TSA+DAC induced the expression of ARHI. Furthermore, reduced cell proliferation, cell cycle arrest and enhanced apoptosis were observed for both groups compared to controls. However, a G1/S cell cycle arrest was observed for the pcDNA3.1(+)-ARHI group, while a G2 cell cycle arrest was observed for the TSA+DAC group. The latter effect was reversed with the introduction of ARHI-targeted siRNA in combination with TSA+DAC treatment. To further clarify these observations, expression levels of several key cell cycle regulators were analyzed by western blotting. The pcDNA3.1(+)-ARHI group exhibited higher expression levels of p53, p21 and p27, and lower levels of cyclin D1, CDK4 and CDK6 when compared to the control group (P<0.05). For the TSA+DAC group, higher levels of p53, p21, cyclin B1 and Chk1 were detected, concomitant with lower levels of CDK1, when compared to the control group. Taken together, these results suggest that ARHI acts as a tumor suppressor gene in MDA-MB-231 cells and, although TSA+DAC can block the cells at different cell cycle phage, the antitumor effect is ARHI-dependent.

9 October 2018 in Oncology Reports
Verified
Journal Article
Open access
PDF file
SHShangke Huang
Shangke Huang
NYNa Yuan
Na Yuan
GWGuanying Wang
Guanying Wang
FWFang Wu
Fang Wu
LFLu Feng
Lu Feng
LZLingxiao Zhang
Lingxiao Zhang
Networks of nanotubes and microtubules are highly valued in cellular communication, and collective cancer movement has been revealed to be associated with cell information exchange. In the present study, cellular communication was demonstrated to participate in mammosphere growth, differentiation and collective invasion. By promoting differentiation, networks of cells and microtubule‑like structures were verified. Analyses of cell cycle progression, stemness markers and gene expression indicated that mammospheres had collective characteristics of stemness and differentiation. Invasion assays revealed that networks of microtubule‑like structures promoted collective invasion. Conversely, using anti‑angiogenic intervention, the growth of stem‑like mammospheres and cellular communication links were effectively inhibited. In vivo experiments revealed that cellular communication promoted tumor growth and metastasis through the formation of nodular fusion, cluttered microtubule‑like structures and cancer stem cells, as well as vascular niches. In conclusion, the present results demonstrated that a network of cells and structures were largely present in mammosphere cellular communication in vitro and in vivo. Therefore, blocking cellular communication may prove beneficial in halting the progression of mammary tumors.

1 July 2014
Verified
Journal Article
Closed access
NYNa Yuan
Na Yuan
GXGuo-Hong Xin
Guo-Hong Xin
XZXiao-Xiao Zuo
Xiao-Xiao Zuo
SHShang-Ke Huang
Shang-Ke Huang
YWYing Wang
Ying Wang
XZXin-Han Zhao
Xin-Han Zhao

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
CFChongwen Fang
Chongwen Fang
MWMin Wu
Min Wu
JLJing Lv
Jing Lv
YZYanping Zhang
Yanping Zhang
QZQinyun Zheng
Qinyun Zheng
SHShangke Huang
Shangke Huang
Moving from an association signal to a clinically credible biomarker requires several links that are often conflated: verified variant identity, aligned allelic effects, reproducible gene‐level association, relevant cellular expression, and a plausible functional consequence. We developed a source‐aware multiomics framework to assess MPHOSPH6 in lung adenocarcinoma (LUAD) while keeping those evidence classes separate. Six prespecified rsIDs were recovered from the harmonized TRICL LUAD dataset, of which five reached p < 5 × 10 − 8. Only rs112333466 and rs76474922 were available with alignable alleles in FinnGen R10, and both showed concordant directions. Fixed‐effect estimates were OR = 1.592 for rs112333466‐T (95% CI, 1.401–1.809; p = 9.91 × 10 − 13) and OR = 0.819 for rs76474922‐C (95% CI, 0.773–0.867; p = 1.03 × 10 − 11). In a prespecified two‐variant GTEx v8 lung model, genetically predicted MPHOSPH6 expression was positively associated with LUAD in TRICL ( Z = 3.341, p = 8.35 × 10 − 4) and FinnGen ( Z = 2.697, p = 0.0070). This gene‐level result did not establish colocalization or connect MPHOSPH6 to the six susceptibility rsIDs. Patient‐level analysis of 89,241 immune cells from six paired tumor and normal‐adjacent lung samples found no significant difference in MPHOSPH6 pseudobulk abundance (exact paired Wilcoxon p = 0.3125). None of 688 lung‐lineage pharmacogenomic tests remained significant after false‐discovery‐rate correction. Ten recorded MPHOSPH6 missense alleles, including five ClinVar variants of uncertain significance, were curated; structural analysis identified I58 at an experimental RNA‐exosome interface and defined a focused perturbation series. MPHOSPH6 is therefore supported as a human–variation‐informed candidate for functional evaluation, not as a validated LUAD biomarker, pathogenic gene, drug‐response predictor, or therapeutic target.